Gables Capital Management’s GSK GSK Stock Holding History

Gables Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-775	Closed	-$35K	–	354
2021 Q1	$35K	Hold	775	–	–	0.02%	249
2020 Q4	$36K	Hold	775	–	–	0.02%	228
2020 Q3	$36K	Hold	775	–	–	0.02%	223
2020 Q2	$40K	Hold	775	–	–	0.03%	200
2020 Q1	$37K	Hold	775	–	–	0.03%	203
2019 Q4	$46K	Hold	775	–	–	0.03%	205
2019 Q3	$41K	Hold	775	–	–	0.03%	218
2019 Q2	$39K	Sell	775 -200	-21%	-$10K	0.03%	204
2019 Q1	$51K	Hold	975	–	–	0.04%	181
2018 Q4	$47K	Hold	975	–	–	0.04%	181
2018 Q3	$49K	Hold	975	–	–	0.04%	188
2018 Q2	$49K	Buy	+975	New	+$49.1K	0.04%	186

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Gables Capital Management's GSK Position: Q2 2021 in Review

Gables Capital Management sold out of GSK (GSK) in Q2 2021, closing a stake of 775 shares — an estimated $35K sold.

Gables Capital Management first reported a position in GSK in Q2 2018 and held it in 12 quarters. The position peaked at $51K in Q1 2019. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

Gables Capital Management reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
Gables Capital Management sold 775 GSK shares in Q2 2021, an estimated $35K.
Gables Capital Management first reported a position in GSK in Q2 2018 and held it in 12 quarters.
Gables Capital Management's GSK position peaked at $51K in Q1 2019.
798 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on Gables Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.